Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 3 selected

Guidance programme

Showing 1 to 25 of 906

TitleReference numberPublishedLast updated
Mirikizumab for treating moderately to severely active Crohn's diseaseTA1080
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
Dapagliflozin for treating chronic kidney diseaseTA1075
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Sparsentan for treating primary IgA nephropathyTA1074
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Linzagolix for treating symptoms of endometriosisTA1067
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Cenobamate for treating focal onset seizures in epilepsyTA753
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058

Results per page

  1. 10
  2. 25
  3. 50
  4. All